AVAX Technologies, Inc.
(Public, OTC:AVXT.PK)
AVAX Technologies, Inc. has gone through a vast number of ups and downs throughout 2006 to 2007. At this time StocksHaven Investments profiles the company and takes look at what investors may expect within the near future.
AVAX had a number of expectations to meet in order to sustain ongoing business operations: equity financing, FDA registration for phase II and phase III clinical trials, and collaborations and expansions.The successful completion of these goals has paved the way for a fresh and optimistic 2008 and thus 2009 for AVAX. Having raised $10M in equity financing, and $1.2M in a collaboration of CTCA on the OVARIAN trials (Ovax), dilution should be out of the question for the remainder of 2010. Despite all of this, there remains one main reason which makes AVAX a solid company: their pipeline which targets some of the fastest growing markets within the biotech medical industry. MVax is aiming towards a $775M Melanoma treatment market by 2010, while Ovax looks to enter a potential Ovarian cancer drug market of $1.6B by 2016. Moreover, AVAX’ currently trades at a highly undervalued estimated market cap of 27.10M when comparred to a similar cancer treatment company in Cell Therapeutics (NASDAQ:CTIC), which is sitting at roughly 627.11M market cap without any drugs currently being approved by the FDA. 2010 should prove to be an eventful year for this up and coming rising small cap biotech. MVax® is AVAX’s lead product candidate and it is currently in an International Phase III Registration trial with centers in the U.S., Europe and Israel. To date over 600 patients have been treated with the AC Vaccine Technology.
Quelle:
www.stockshaven.com/...rials-news-for-its-pipeline-otcavxt-pk/
Die Ergebnisse von der Phase III sollen im Januar 2010 vorgelegt werden...
Quelle:www.clinicaltrials.gov/ct2/show/...477906?term=MVax&rank=1
So jetzt kann man hier weiter diskutieren...
Gruß
wlad
(Public, OTC:AVXT.PK)
AVAX Technologies, Inc. has gone through a vast number of ups and downs throughout 2006 to 2007. At this time StocksHaven Investments profiles the company and takes look at what investors may expect within the near future.
AVAX had a number of expectations to meet in order to sustain ongoing business operations: equity financing, FDA registration for phase II and phase III clinical trials, and collaborations and expansions.The successful completion of these goals has paved the way for a fresh and optimistic 2008 and thus 2009 for AVAX. Having raised $10M in equity financing, and $1.2M in a collaboration of CTCA on the OVARIAN trials (Ovax), dilution should be out of the question for the remainder of 2010. Despite all of this, there remains one main reason which makes AVAX a solid company: their pipeline which targets some of the fastest growing markets within the biotech medical industry. MVax is aiming towards a $775M Melanoma treatment market by 2010, while Ovax looks to enter a potential Ovarian cancer drug market of $1.6B by 2016. Moreover, AVAX’ currently trades at a highly undervalued estimated market cap of 27.10M when comparred to a similar cancer treatment company in Cell Therapeutics (NASDAQ:CTIC), which is sitting at roughly 627.11M market cap without any drugs currently being approved by the FDA. 2010 should prove to be an eventful year for this up and coming rising small cap biotech. MVax® is AVAX’s lead product candidate and it is currently in an International Phase III Registration trial with centers in the U.S., Europe and Israel. To date over 600 patients have been treated with the AC Vaccine Technology.
Quelle:
www.stockshaven.com/...rials-news-for-its-pipeline-otcavxt-pk/
Die Ergebnisse von der Phase III sollen im Januar 2010 vorgelegt werden...
Quelle:www.clinicaltrials.gov/ct2/show/...477906?term=MVax&rank=1
So jetzt kann man hier weiter diskutieren...
Gruß
wlad
